Please login to the form below

Not currently logged in


This page shows the latest Vitrakvi news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology, personalised medicine continues to drive pharma sector

Immuno-oncology, personalised medicine continues to drive pharma sector

A recent example of this issue is Bayer’s tumour-agnostic drug Vitrakvi (larotrectinib), which targets all solid tumours that display a NTRK gene fusion regardless of cancer type, but was ... Despite rejecting Vitrakvi, NICE said that it was in

Latest news

More from news
Approximately 4 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... Vitrakvi(larotrectinib) gained FDA approval in late November to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...